| Drug General Information |
| Drug ID |
D0GC1Y
|
| Former ID |
DNC002499
|
| Drug Name |
Nitroarginine
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C6H13N5O4
|
| Canonical SMILES |
C(CC(C(=O)O)N)CN=C(N)N[N+](=O)[O-]
|
| InChI |
1S/C6H13N5O4/c7-4(5(12)13)2-1-3-9-6(8)10-11(14)15/h4H,1-3,7H2,(H,12,13)(H3,8,9,10)
|
| InChIKey |
MRAUNPAHJZDYCK-UHFFFAOYSA-N
|
| CAS Number |
CAS 2149-70-4
|
| PubChem Compound ID |
|
| PubChem Substance ID |
547830, 5551115, 7643582, 14843635, 26748627, 26748628, 29223464, 49999410, 57322247, 79890155, 85088164, 103839839, 103939235, 104306196, 117526180, 117526181, 117543512, 118783636, 124880896, 124880897, 125539897, 126692008, 128635502, 134983332, 140502415, 140976466, 143776184, 162303510, 164756923, 164813535, 165754272, 176332387, 177513126, 179331489, 206245003, 223664254, 225249570, 227149403, 237613584, 241269501
|
| Target and Pathway |
| Target(s) |
Nitric-oxide synthase, brain |
Target Info |
Inhibitor |
[1]
|
|---|
| Nitric-oxide synthase, endothelial |
Target Info |
Inhibitor |
[1]
|
|
BioCyc Pathway
|
Citrulline-nitric oxide cyclePWY-4983:Citrulline-nitric oxide cycle
|
|
KEGG Pathway
|
Arginine and proline metabolism
|
|
Metabolic pathways
|
|
Calcium signaling pathway
|
|
Phagosome
|
|
Circadian entrainment
|
|
Long-term depression
|
|
Salivary secretion
|
|
Alzheimer's disease
|
|
Amyotrophic lateral sclerosis (ALS)hsa00330:Arginine and proline metabolism
|
|
cGMP-PKG signaling pathway
|
|
HIF-1 signaling pathway
|
|
Sphingolipid signaling pathway
|
|
PI3K-Akt signaling pathway
|
|
VEGF signaling pathway
|
|
Platelet activation
|
|
Estrogen signaling pathway
|
|
Oxytocin signaling pathway
|
|
NetPath Pathway
|
EGFR1 Signaling PathwayNetPath_8:Wnt Signaling Pathway
|
|
PANTHER Pathway
|
CCKR signaling map STP00005:Angiogenesis
|
|
Endothelin signaling pathway
|
|
Interleukin signaling pathway
|
|
PI3 kinase pathway
|
|
VEGF signaling pathway
|
|
Pathway Interaction Database
|
Plasma membrane estrogen receptor signaling
|
|
Validated transcriptional targets of AP1 family members Fra1 and Fra2
|
|
Angiopoietin receptor Tie2-mediated signaling
|
|
Thromboxane A2 receptor signaling
|
|
SHP2 signaling
|
|
VEGFR1 specific signals
|
|
Signaling events mediated by VEGFR1 and VEGFR2
|
|
PAR1-mediated thrombin signaling events
|
|
PathWhiz Pathway
|
Arginine and Proline Metabolism
|
|
Reactome
|
ROS production in response to bacteria
|
|
Nitric oxide stimulates guanylate cyclaseR-HSA-1222556:ROS production in response to bacteria
|
|
Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
|
|
eNOS activation
|
|
Nitric oxide stimulates guanylate cyclase
|
|
VEGFR2 mediated vascular permeability
|
|
WikiPathways
|
Monoamine Transport
|
|
Myometrial Relaxation and Contraction Pathways
|
|
Amyotrophic lateral sclerosis (ALS)
|
|
Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis
|
|
Spinal Cord Injury
|
|
Alzheimers Disease
|
|
Effects of Nitric Oxide
|
|
Serotonin Transporter ActivityWP554:ACE Inhibitor Pathway
|
|
EGF/EGFR Signaling Pathway
|
|
JAK/STAT
|
|
Corticotropin-releasing hormone
|
|
AGE/RAGE pathway
|
|
Endothelin Pathways
|
|
Leptin signaling pathway
|
|
Metabolism of nitric oxide
|
|
Angiogenesis
|
| References |
| REF 1 | Crystal structure of nitric oxide synthase bound to nitro indazole reveals a novel inactivation mechanism. Biochemistry. 2001 Nov 13;40(45):13448-55. |
|---|
